Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

(2015) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis

(2015) K. Hu et al.   BMJ Open

Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy

(2014) Yong Park et al.   SpringerPlus

Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients

(2013) M Pichler et al.   BRITISH JOURNAL OF CANCER

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)

(2013) Ana M. Molina et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

(2013) Daniel YC Heng et al.   LANCET ONCOLOGY

Molecular Markers to Predict Response to Therapy

(2013) Jesus Garcia-Donas et al.   SEMINARS IN ONCOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma

(2011) Daniel Keizman et al.   EUROPEAN JOURNAL OF CANCER

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

(2009) Daniel Y.C. Heng et al.   JOURNAL OF CLINICAL ONCOLOGY